Ajmaline challenge in young individuals with suspected Brugada syndrome

Pacing Clin Electrophysiol. 2011 Jun;34(6):736-41. doi: 10.1111/j.1540-8159.2011.03033.x. Epub 2011 Feb 8.

Abstract

Background: The clinical characteristics and the results of ajmaline challenge in young individuals with suspected Brugada syndrome (BS) have not been systematically investigated.

Methods: Among a larger series of patients included in the BS database of our Department, 179 patients undergoing ajmaline challenge were included in the study and categorized in two groups according to age: group 1 (<18 years old) and group 2 (≥18 years old). Clinical features and results of the ajmaline challenge of each group were compared.

Results: Young individuals were more often asymptomatic compared to adult patients (P = 0.002). They showed a higher number of normal ECGs (P = 0.023), a lower percentage of Brugada type II electrocardiographic pattern compared to the adult population (P = 0.011), and a comparable amount of spontaneous Brugada type III electrocardiographic pattern (P = 0.695). Ajmaline provoked a higher degree of intraventricular conduction delay (P = 0.002) and higher degree of prolongation of the ventricular repolarization phase (P = 0.013) in young individuals but its pro-arrhythmic risk was comparable in the two groups (P = 0.684). Furthermore, inducibility of ventricular arrhythmias in young patients with a positive ajmaline test was comparable to that of the adults with a positive ajmaline test (P = 0.694).

Conclusions: The present study demonstrates the low-risk profile of the ajmaline test in young patients when performed by experienced physicians and nurses in an appropriate environment.

MeSH terms

  • Adolescent
  • Ajmaline* / adverse effects
  • Anti-Arrhythmia Agents / adverse effects
  • Brugada Syndrome / diagnosis*
  • Child
  • Child, Preschool
  • Electrocardiography / drug effects*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Young Adult

Substances

  • Anti-Arrhythmia Agents
  • Ajmaline